Eravacycline has been shown to have broad-spectrum activity against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). We compared the activity of eravacycline with that of tigecycline in CRE isolates cultured from patients at an academic medical centre. Eravacycline was more potent than tigecycline [mean minimum inhibitory concentration (MIC) ratio = 0.76, 95% confidence interval 0.66-0.87]; however, the MIC observed for eravacycline was higher than previously reported at 4 μg/mL. Future studies are necessary to elucidate the mechanism driving this difference.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijantimicag.2020.106178 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Activity of cefiderocol in combination with tetracycline analogues against carbapenem-resistant Acinetobacter baumannii.
J Antibiot (Tokyo)
December 2024
Department of Respiratory Medicine, An Qiu People's Hospital, An Qiu, China.
Therapeutic options for carbapenem-resistant Acinetobacter baumannii (CA-AB) are quite limited. Cefiderocol, a novel siderophore cephalosporin, has shown potent in vitro activity against CR-AB, and new tetracycline analogues such as eravacycline and omadacycline have been available in recent years. However, the synergism of cefiderocol with tetracycline analogues against CR-AB has not been well investigated.
View Article and Find Full Text PDFActivity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii.
Biomed Pharmacother
December 2024
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain; Ciber de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Introduction: The rise in multidrug-resistant bacteria challenges clinical microbiology. Tigecycline, eravacycline, and omadacycline show promise against carbapenem-resistant Enterobacterales and Acinetobacter baumannii. This study evaluates their activity and resistance mechanisms.
View Article and Find Full Text PDFactivities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China.
Front Microbiol
November 2024
Department of Clinical Laboratory, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Introduction: Eravacycline (ERV), a novel tetracycline derivative, exhibits broad-spectrum antibacterial activity, but data on the bacterial activity against Chinese bacterial isolates are very scarce. This study aims to evaluate the activity of eravacycline against the common Gram-positive and Gram-negative bacteria isolates in Guangdong, China.
Methods: The clinical isolates were collected from four centers between 1 November 2023 and 31 January 2024, and the susceptibility of eravacycline (MIC, MIC, and MIC) was determined using broth microdilution as a reference method and E-TEST strips to evaluate their consistency.
Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion.
J Antimicrob Chemother
November 2024
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Article Synopsis
- - The study evaluated the effectiveness of various methods in determining how resistant carbapenem-resistant Acinetobacter baumannii (CRAB) is to the antibiotic eravacycline, using 587 CRAB strains collected from a hospital over four years.
- - Using the broth microdilution (BMD) method as a standard, the study found high susceptibility rates for different testing methods: BMD (98.13%), MIC test strip (MTS) (97.96%), and disc diffusion (DD) (97.61%).
- - Results showed strong agreement between the MTS and DD methods with BMD, suggesting that both MTS and DD are reliable alternatives for testing eravacycline efficacy in clinical labs.*
Comparison of antimicrobial activities and resistance mechanisms of eravacycline and tigecycline against clinical isolates in China.
Front Microbiol
September 2024
Key Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Article Synopsis
- Tigecycline (TGC) is used to treat carbapenem-resistant (CRAB) infections, while eravacycline (ERV) is a newer tetracycline that could provide additional treatment options, but their resistance mechanisms are not fully understood.
- A study analyzed 492 clinical isolates from hospitalized patients in China, comparing the resistance characteristics of ERV and TGC, finding that ERV generally had lower minimum inhibitory concentrations (MICs) than TGC.
- The results showed distinct resistance mechanisms, with certain genetic mutations and insertions contributing to the resistance; specifically, high expression levels in resistant strains were linked to the presence of insertions, impacting the effectiveness of both ERV and TGC
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!